|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2017
Schoffski, P.; Wozniak, A.; Stacchiotti, S.; Rutkowski, P.; Blay, J.-Y.; Lindner, L. H.; Strauss, S. J.; Anthoney, A.; Duffaud, F.; Richter, S.; Grünwald, V.; Leahy, M. G.; Reichardt, P.; Sufliarsky, J.; Graaf, W. T. van der; Sciot, R.; Debiec-Rychter, M.; Cann, T. van; Marreaud, S.; Lia, M.; Raveloarivahy, T.; Collette, L. und Bauer, S.
(2017):
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
In: Annals of Oncology, Bd. 28, Nr. 12: S. 3000-3008
2016
Ray-Coquard, I.; Rizzo, E.; Blay, J. Y.; Casali, P.; Judson, I.; Krarup Hansen, A.; Lindner, L. H.; Dei Tos, A. P.; Gelderblom, H.; Marreaud, S.; Litiere, S.; Rutkowski, P.; Hohenberger, P.; Gronchi, A. und Graaf, W. T. van der
(2016):
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
In: Gynecologic Oncology, Bd. 142, Nr. 1: S. 95-101